TFCP2 and hepatocellular carcinoma: Our new findings that LSF interacts with α-tubulin and SET8 and that FQI1 hinders the LSF-α-tubulin interaction may relate to the impact of LSF inhibitors in hepatocellular carcinoma cells and tumors.